Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or 'the Company')…
Big pharma move to dispense GLP-1s to your door condemned by doctors
Eli Lilly's new online platform LillyDirect will dispense certain medicines, starting with Mounjaro, directly to a patient's door. Doctors and pharmacists have criticised the move, arguing it poses a risk to patient safety. Eli Lilly has defended…
China eyes competition with Big Pharma over next 5 years
China is making it clear that it wants to become a powerhouse on a par with large Western pharmaceutical companies in the near future, and not just strike licensing deals for promising new drug candidates. Why it matters: Some experts warn that big…
Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type…
OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program
OnDosis AB ('OnDosis'), a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform, and Adare Pharma Solutions ('Adare'), a technology-driven…
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in…
Arcus agrees to buy SK Pharma from Syz Capital and Saturnus Capital
A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked
The second phase of the Section 232 tariff on imported patented drugs and their key ingredients began on September 29, 2026. That extended a duty that has covered a first group of named companies since July 31, 2026, to every other drugmaker. The…
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated 'Moderate Buy' by Wall Street Analysts
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) has earned a consensus recommendation of 'Moderate Buy' from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock…
Nxera Announces Successful Resolution of miniG Patent Infringement Action
Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited…
Avalyn Pharma (NASDAQ:AVLN) Stock Jumps 6.4% - Here's What Happened
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares were up 6.4% on Wednesday. The stock traded as high as $28.87 and last traded at $28.84. 160,187 shares changed hands during trading, a decline of 48% from the average daily volume of…
Boehringer, Zealand Obesity Drug's 13% Weight Loss Disappoints
Boehringer Ingelheim GmbH 's and Zealand Pharma A/S 's experimental obesity drug survodutide helped patients with diabetes shed as much as 13.1% of their weight, disappointing investors. Zealand shares fell as much as 13% in Copenhagen trading…
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST)
Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. My base case values AQST at $8, reflecting ~70% upside, but I would only buy closer to $3.50 for an adequate margin of…
ALK expands strategic tablet supply partnership with Catalent
Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis) tablet formulation technology. Supply robustness secured with prioritised manufacturing capacity increase of ~40% to 1.1 billion tablets annually from early 2030s.
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a…
Receive a Daily briefing on Pharma Industry News
Get Started